Effect of Prontosan Wound Irrigation Solution on Venous Ulcers

Sponsor
Calvary Hospital, Bronx, NY (Other)
Overall Status
Completed
CT.gov ID
NCT01048307
Collaborator
B. Braun Medical SA (Industry)
20
1
2
13
1.5

Study Details

Study Description

Brief Summary

Objective:

To evaluate the efficacy and safety of Prontosan® Wound Irrigation Solution in the treatment of hard-to-heal venous leg ulcers compared to wound irrigation with saline solution

Methodology:

Randomised, controlled multi-centre, prospective clinical trial

Planned number of subjects:

20 patients in experimental group (Prontosan® Wound Irrigation Solution) 8 patients in control group (wound irrigation with saline)

Products under investigation:

Prontosan® Wound Irrigation Solution

Study Duration:

3-4 weeks

Condition or Disease Intervention/Treatment Phase
  • Device: Prontosan wound irrigation solution
N/A

Detailed Description

Investigational product, dose and administration:

Prontosan® Wound Irrigation Solution (experimental group) and saline solution (control group) will be applied at inclusion and reapplied after dressing changes.

The treatment scheme is as follows:
  1. Prontosan® Wound Irrigation Solution (experimental group):
  • cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the immediate wound in the form of a moist compress and removed after approximately 15 minutes;

  • placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;

  • fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).

  1. Saline (control group):
  • cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;

  • placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;

  • fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).

Dressings will be changed and the treatment procedure will be repeated in the clinic 2x/weekly or more. The efficacy of the treatment procedure will be evaluated on the basis of a 2 week observation period.

Treatment efficacy assessment:
  • Assessment of clinical signs and symptoms at entry to the study and after one and two weeks.

  • Quantitative and qualitative microbiological analysis at entry to the study and after two weeks.

  • Wound planimetry using PictZar® CDM at entry to the study and after two weeks.

Primary aim:
  • clinical signs assessed by:
  1. reduction of slough and necrotic tissue

  2. control of exudate

  3. presence of granulation tissue

  • reduction of inflammatory signs (surrounding skin)

  • reduction in wound size (assessed by wound planimetry)

  • reduction of bacterial load (quantitative and qualitative microbiological

Secondary aim:
  • tolerance and safety assessment:
  1. adverse drug reaction

  2. adverse events

  3. early withdrawal from the study

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomised, Controlled, Clinical Trial on the Safety and Efficacy of Prontosan Wound Irrigation Solution Compared to Standard Therapy in the Treatment of Hard-to-Heal Venous Leg Ulcers
Study Start Date :
Jun 1, 2009
Actual Primary Completion Date :
Jul 1, 2010
Actual Study Completion Date :
Jul 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Experimental: Prontosan wound irrigation solution

Prontosan® Wound Irrigation Solution (experimental group): cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the wound in the form of a moist compress and removed after approx.15 minutes; placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution; fixing the dressing to the wound using multilayered elastic compression bandaging (Profore®bandaging system).

Device: Prontosan wound irrigation solution
Prontosan® Wound Irrigation Solution (experimental group): • Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound Saline (control group): cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes; placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline; fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
Other Names:
  • Wound irrigation solution containing PHMB
  • Polihexanide
  • Betaine
  • Wound cleanser
  • Placebo Comparator: Saline irrigation (standard care control)

    Saline (control group): cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes; placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline; fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).

    Device: Prontosan wound irrigation solution
    Prontosan® Wound Irrigation Solution (experimental group): • Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound Saline (control group): cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes; placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline; fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
    Other Names:
  • Wound irrigation solution containing PHMB
  • Polihexanide
  • Betaine
  • Wound cleanser
  • Outcome Measures

    Primary Outcome Measures

    1. Reduction of bacterial burden (quantitative bacteriology) Reduction in slough and necrotic tissue (clinical score) Amount and quality of granulation tissue (clinical score) Exudate type and amount (clinical score) [weekly]

    Secondary Outcome Measures

    1. Adverse device effect (s) Adverse events [volunteered at any time or during weekly evaluation visits]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 95 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • males and females aged at least 18 with wounds of venous aetiology (documented by targeted exams) located in the lower limbs

    • Ankle Brachial Index (ABI) ≥ 0.7

    • patients who have not had an antimicrobial (systemic antibiotic or topical antiseptic) over the 30 days before joining the study

    Exclusion Criteria:

    Exclusion criteria

    • age below 18 years

    • presence of clinical infection, or current use of antiseptics or antibiotics

    • chronic wounds of long duration (>30cm2 and >1 year duration)

    • involvement in other wound related trials within the past 30 days

    • sensitivity to any of the components of Prontosan® or dressing material

    • intolerance to compression therapy

    • active osteomyelitis in the ulceration area

    • active rheumatoid arthritis (RA) requiring any immunosuppressive therapy

    • collagen vascular disease active treated with steroids

    • chronic diseases that could impact the course of the study (malicious cancer, TB, AIDS, mental illnesses)

    • plasma protein below 4 g/dl

    • anaemia: haemoglobin below 10 g/dl

    • both, controlled and uncontrolled diabetics (type 1 or 2)

    • patients on any rheological agents (not including aspirin)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Calvary hospital center for curative and palliative wound care Bronx New York United States 10461

    Sponsors and Collaborators

    • Calvary Hospital, Bronx, NY
    • B. Braun Medical SA

    Investigators

    • Principal Investigator: Oscar M Alvarez, PhD, Calvary Hospital, Wound Care
    • Study Director: Martin Wendelken, RN, DPM, Calvary Hospital, Wound Care

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01048307
    Other Study ID Numbers:
    • OPM-I-H-0902
    First Posted:
    Jan 13, 2010
    Last Update Posted:
    Aug 17, 2010
    Last Verified:
    Aug 1, 2010

    Study Results

    No Results Posted as of Aug 17, 2010